Financial Data and Key Metrics Changes - The company has experienced stable and continuous growth in its pharmacological efficacy and modeling segment over the past few years [1] Business Line Data and Key Metrics Changes - The antibody molecules segment, referred to as the "Thousand Trees and Ten Thousand Branches" business, has developed nearly a thousand antibody molecules based on the company's proprietary technology [1] Market Data and Key Metrics Changes - The company aims to establish itself as a global biotechnology firm, leveraging its proprietary technology to expand its market presence [1] Company Strategy and Development Direction - The company is focused on becoming a global biotechnology leader, emphasizing the development of versatile antibodies through its proprietary technology [1] Management Comments on Operating Environment and Future Outlook - Management has highlighted the stable growth in their pharmacological efficacy and modeling segment, indicating a positive outlook for future performance [1] Other Important Information - The company is positioned to leverage its proprietary technology to enhance its product offerings and market reach [1] Q&A Session Summary - No specific questions and answers were provided in the content [1]

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 410,499 thousand, representing a 25.6% increase compared to RMB 326,836 thousand for the same period in 2023[2] - Gross profit for the same period was RMB 305,493 thousand, up 29.8% from RMB 235,364 thousand year-on-year[2] - The loss before tax decreased significantly by 75.1% to RMB 47,077 thousand from RMB 189,389 thousand in the previous year[2] - The net loss for the period was RMB 50,673 thousand, a 73.3% improvement compared to RMB 189,809 thousand in the prior year[2] - Basic and diluted loss per share improved to RMB 0.13 from RMB 0.48, reflecting a 75.0% reduction in loss per share[5] - Cash generated from operating activities was RMB 29,608 thousand, a turnaround from cash used of RMB 17,569 thousand in the same period last year[2] - Total revenue for the six months ended June 30, 2024, was RMB 410,499,000, an increase from RMB 326,836,000 for the same period in 2023, representing a growth of approximately 25.5%[14] - The company reported a net loss before tax of RMB 50,673,000 for the six months ended June 30, 2024, a decrease in loss compared to RMB 189,808,000 for the same period in 2023[30] - The net loss for the first half of 2024 was RMB 50.7 million, a decrease of 73.3% compared to the same period last year[37] Revenue Breakdown - Gene editing services generated revenue of RMB 34,606,000, up from RMB 33,429,000, reflecting a growth of 3.5%[14] - Preclinical pharmacology services revenue decreased to RMB 81,552,000 from RMB 89,541,000, a decline of approximately 8.8%[14] - Sales of model animals significantly increased to RMB 175,772,000 from RMB 115,219,000, marking a growth of about 52.6%[14] - Antibody development revenue rose to RMB 118,200,000 from RMB 88,245,000, an increase of approximately 33.9%[14] - Revenue from external customers in the United States increased significantly to RMB 218,444,000 for the six months ended June 30, 2024, compared to RMB 116,577,000 in the same period of 2023, marking an increase of 87.5%[21] - One customer accounted for over 10% of total revenue, with transactions amounting to RMB 50,886,000 for the six months ended June 30, 2024, compared to RMB 50,441,000 in the same period of 2023[14] Assets and Liabilities - Current assets increased to RMB 766,144 thousand from RMB 723,050 thousand as of June 30, 2023[6] - Current liabilities decreased slightly to RMB 572,607 thousand from RMB 577,616 thousand year-on-year[6] - Total assets decreased to RMB 1,859,615 thousand from RMB 1,871,792 thousand as of June 30, 2023[6] - The company's equity attributable to shareholders decreased to RMB 739,692 thousand from RMB 785,886 thousand as of December 31, 2023[8] - Trade receivables from third parties increased to RMB 199.4 million as of June 30, 2024, compared to RMB 153.6 million at the end of 2023[32] - Trade payables to third parties decreased to RMB 91.7 million as of June 30, 2024, down from RMB 115.1 million at the end of 2023[34] Research and Development - Research and development expenses for the first half of 2024 were RMB 161.7 million, a substantial decrease of 34.8% from the previous year[38] - The company has completed most of the work on its proprietary large-scale human antibody screening program, QianShuWanKang, by Q3 2023, with over 400,000 human antibody sequences covering approximately 1,000 targets established by June 30, 2024[45] - The company has a diverse pipeline of candidate drugs targeting new drug targets or differentiated efficacy or safety, validated through preclinical and clinical studies[41] - The company has established a unique scalable antibody development process, creating a diverse and high-quality human antibody library for pharmaceutical companies[45] - The company has developed a series of second-generation products based on the B-NDG mouse to address issues related to hematopoietic cell differentiation and immune cell development[68] Clinical Trials and Drug Development - The core product YH001, a humanized anti-CTLA-4 IgG1 monoclonal antibody, has shown a 19.2% objective response rate and a 61.5% disease control rate in a clinical trial involving 29 patients[47] - YH003, a humanized IgG2 agonistic monoclonal antibody targeting CD40, has demonstrated a 27.9% objective response rate and an 81.4% disease control rate in a study involving 47 patients with pancreatic ductal adenocarcinoma[50] - The company has received IND approvals from multiple regulatory agencies, including the FDA and China's National Medical Products Administration, to conduct Phase II clinical trials for YH003[49] - The company has successfully negotiated to reclaim the rights to YH001 from Tracon Pharmaceuticals, which has entered bankruptcy, allowing for further clinical research exploration[48] - YH004 has initiated a Phase I clinical trial in Australia, with 17 patients enrolled and good safety and tolerability observed at doses up to 3.0 mg/kg[56] Strategic Partnerships and Collaborations - The company has signed approximately 150 drug cooperation development/authorization/transfer agreements, with about 50 new agreements signed in the first half of 2024, a growth of approximately 230% year-on-year[37] - The company has established a strategic partnership with leading biopharmaceutical companies to enhance the success rate of its candidate drugs through complementary expertise and resources[40] - The collaboration with Syncromune aims to develop and commercialize YH003 using the Syncrovax™ technology for intratumoral immunotherapy[52] - The company has entered into licensing and trial collaboration agreements with several multinational pharmaceutical companies, including Merck Healthcare KGaA and Johnson & Johnson, which will generate upfront payments, milestone payments, and sales royalties[77] Corporate Governance and Compliance - The audit committee has reviewed the interim financial results for the six months ending June 30, 2024, and found them compliant with relevant accounting standards[117] - The independent auditor has conducted a review of the interim financial data in accordance with the applicable standards[118] - The company remains committed to high standards of corporate governance to protect shareholder interests[114] - The board believes that the current structure of having the same individual serve as both Chairman and CEO is beneficial for strategic decision-making[114] Market Expansion and Sales Growth - The company has expanded its overseas sales team and established a subsidiary in Germany to enhance local customer coverage, resulting in significant sales growth during the reporting period[62] - The company has established a sales system covering the Asia-Pacific, North America, and Europe, with a focus on expanding overseas markets and maintaining rapid growth in overseas sales revenue[83] - The total revenue from overseas business continues to increase as a proportion of the company's total revenue[83] - The company has created over 3,300 unique gene-edited mouse/cell line projects for antibody discovery and disease modeling, enhancing its preclinical CRO services[63] Financial Position and Cash Flow - As of June 30, 2024, the total cash and cash equivalents amounted to approximately RMB 411.2 million, slightly down from RMB 417.7 million as of December 31, 2023[105] - The outstanding loans as of June 30, 2024, were approximately RMB 395.5 million, up from RMB 234.8 million as of June 30, 2023[108] - The asset-liability ratio as of June 30, 2024, was 2.27, compared to 2.10 as of December 31, 2023[108] - The net cash flow from operating activities for the six months ended June 30, 2024, was RMB 29.6 million, a significant improvement from a cash outflow of RMB 17.6 million for the same period in 2023[106] Future Outlook - The company aims to achieve or approach breakeven in 2024 by focusing on cost control and operational efficiency[94] - Continued investment in R&D is planned to strengthen core business advantages, particularly in antibody development and preclinical services[94] - The focus will remain on developing innovative animal models and expanding the portfolio of fully human antibodies, including bispecific antibodies and ADCs[94]

Financial Performance - Total revenue for 2023 reached RMB 717 million, a 34% increase compared to 2022[6]. - Overseas business revenue amounted to RMB 408 million, representing a 66% growth from 2022[6]. - Losses decreased to RMB 383 million, reflecting a 36% reduction from 2022[6]. - The company's sales revenue grew over 34.3% in 2023, with antibody development revenue reaching RMB 175.9 million, a 38.6% increase year-on-year[17]. - Revenue from animal model sales amounted to RMB 272.8 million, marking a 61.1% increase compared to the previous year[17]. - The gross profit increased by 29.2% to approximately RMB 506.0 million, with a gross profit margin decreasing from 73.4% in 2022 to 70.6% in 2023 due to operational changes in the Boston facility[142]. - The company achieved significant growth in sales revenue, particularly in overseas sales, and expects to continue narrowing losses in 2024, aiming for a near breakeven[130]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in Q3 2023, representing a 25% year-over-year growth[195]. Research and Development - R&D expenditure decreased to RMB 474 million, a reduction of approximately 32% compared to 2022[6]. - The R&D phase of Project Integrum was completed in 2023, transitioning to collaboration with partners for drug pipeline development[13]. - The overall R&D strategy focuses on self-directing early discovery of drug molecules and advancing promising candidates to the pre-clinical stage[20]. - The company aims to achieve sustainable revenue growth through upfront payments, milestone payments, and royalties from joint development and licensing agreements[20]. - The company has completed most of the work on Project Integrum by December 31, 2023[30]. - The company continues to maintain high R&D investment levels to develop globally competitive animal models and provide high-quality pre-clinical CRO services[67]. - The company is investing heavily in R&D, with a budget increase of 30% to enhance product development and innovation[195]. Antibody Development - The antibody development business generated RMB 176 million in revenue for 2023, a 39% increase from 2022[9]. - The company completed over 900 fully human antibody development projects and established a library of 400,000 to 500,000 antibody sequences[9]. - The antibody development business is expected to maintain a strong growth trajectory with milestone payments anticipated in the coming years[9]. - The company has shifted its antibody development strategy to pre-developing hundreds of thousands of antibody molecules for immediate supply, significantly reducing pre-clinical development time by over 1-2 years compared to traditional methods[31]. - The company has established collaborations with major pharmaceutical companies, including Merck, Gilead, and Neurocrine, enhancing its market presence and development capabilities[34]. Market Expansion - The company aims to further expand overseas markets and increase both the amount and proportion of overseas revenue[11]. - The company plans to further expand into high-margin overseas markets in 2024 to sustain revenue and profit growth[18]. - The company is focused on high-growth potential markets and has expanded its overseas sales team to enhance local customer coverage[66]. - The company has established a German subsidiary and a sales team in Europe in 2022, enhancing its global sales network[11]. - The company is actively developing new products, with 10 new gene editing services expected to launch in the next fiscal year[52]. Clinical Trials and Product Development - YH001, a core product, has shown a favorable safety and efficacy profile in a Phase I clinical trial, achieving an objective response rate (ORR) of 19.2% and a disease control rate (DCR) of 61.5% in patients with advanced solid tumors[38]. - The Phase I/II clinical trial of YH001 in combination with Envafolimab and doxorubicin for soft tissue sarcoma has been approved by the FDA and is currently ongoing, with 176 patients expected to be enrolled[40]. - The ongoing studies of YH003 have shown good tolerability and promising clinical efficacy, with results expected to be reported in the first half of 2024[44]. - The company has entered into a collaboration with Syncromune to jointly develop and commercialize YH003, an intratumoral immunotherapy based on Syncrovax™ technology[46]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the biotech sector[195]. Governance and Management - The company has a strong governance structure with independent directors and supervisors overseeing operations and financial integrity[198]. - The management team includes professionals with extensive experience in finance, human resources, and technical fields, ensuring diverse expertise[200]. - The strategic development committee, which includes key directors, is responsible for guiding the company's future direction and growth initiatives[192]. - The company is focused on maintaining high standards of corporate governance and financial accountability through its board and committee structures[198]. Financial Position - Cash at bank and on hand totaled approximately RMB 417.7 million as of December 31, 2023, down from approximately RMB 626.6 million as of December 31, 2022, primarily due to net losses from business operations[150]. - The Group's net current assets as of December 31, 2023, were approximately RMB 145.4 million, down from RMB 313.3 million as of December 31, 2022[165]. - The Group incurred losses of approximately RMB 383.0 million for the year ended December 31, 2023, compared to losses of approximately RMB 602.2 million for the year ended December 31, 2022[157]. - The Group's outstanding loans were approximately RMB 350.7 million, an increase of 96.1% from RMB 178.8 million as of December 31, 2022[158]. - The effective annual interest rate for the five-year bank loan agreement entered in 2023 was 6%, secured by property mortgages[158].

Investment Rating - The report maintains an "Outperform" rating for Biocytogen Pharmaceuticals [3][8][16] Core Insights - In 2023, Biocytogen achieved a revenue of 717 million yuan, representing a 34% increase, with overseas revenue growing by 66% to 408 million yuan. The gross profit margin was 70.6%, an increase of 2.8 percentage points, while the net loss was reduced to 383 million yuan from 602 million yuan in the previous year [5][18] - The company has completed phased research and development for its "Thousand Mice, Ten Antibodies" project, and has successfully licensed out several clinical pipelines [6][20][21] - The preclinical CRO segment saw significant growth, with annual revenue reaching 541 million yuan, a 33% increase, and a gross margin of 67% [19][20] Financial Summary - Revenue projections for Biocytogen from 2024 to 2026 are estimated at 915 million yuan, 1.127 billion yuan, and 1.357 billion yuan, with year-on-year growth rates of 27.6%, 23.2%, and 20.4% respectively. The net profit is expected to turn positive by 2025, reaching 98 million yuan [10][22] - The company’s valuation is segmented, with the preclinical CRO business valued at 3 billion yuan, antibody development at 1.5 billion yuan, and self-developed pipelines also at 1.5 billion yuan, leading to a total valuation of 6 billion yuan [8][22]

Revenue Growth - Revenue increased by 34.3% to RMB 716.9 million in 2023 compared to RMB 533.9 million in 2022[2] - Revenue from gene editing services increased to RMB 74,325 thousand in 2023, up from RMB 61,075 thousand in 2022, representing a growth of 21.7%[13] - Revenue from preclinical pharmacology and efficacy evaluation services rose to RMB 193,396 thousand in 2023, compared to RMB 176,069 thousand in 2022, a 9.8% increase[13] - Model animal sales revenue surged to RMB 272,805 thousand in 2023, a significant 61.1% increase from RMB 169,328 thousand in 2022[13] - Antibody development revenue grew to RMB 175,870 thousand in 2023, up from RMB 126,887 thousand in 2022, marking a 38.6% increase[13] - Total revenue from customer contracts reached RMB 716,912 thousand in 2023, a 34.3% increase from RMB 533,881 thousand in 2022[13] - Revenue from the United States increased to RMB 301,169 thousand in 2023, up from RMB 178,993 thousand in 2022, a 68.3% growth[24] - Revenue from China grew to RMB 308,610 thousand in 2023, compared to RMB 287,736 thousand in 2022, a 7.3% increase[24] - Revenue from antibody development business reached RMB 175.9 million in 2023, a 38.6% increase year-over-year, while model animal sales revenue grew by 61.1% to RMB 272.8 million[43] - Overseas revenue accounted for 57.0% of total revenue in 2023, reaching RMB 408.3 million, a 65.9% increase compared to the previous year[43] - Total revenue increased by 34.3% from RMB 533.9 million in 2022 to RMB 716.9 million in 2023, driven by growth in model animal sales and antibody development[104] - Model animal sales revenue increased to RMB 272.805 million in 2023, accounting for 38.1% of total revenue[104] - Antibody development revenue grew to RMB 175.870 million in 2023, representing 24.5% of total revenue[104] Profit and Loss - Gross profit rose by 29.2% to RMB 506.0 million in 2023 from RMB 391.8 million in 2022[2] - Pre-tax loss decreased by 36.8% to RMB 380.2 million in 2023 from RMB 601.4 million in 2022[2] - Net loss for the year reduced by 36.4% to RMB 383.0 million in 2023 from RMB 602.2 million in 2022[2] - Basic and diluted loss per share decreased by 39.2% to RMB 0.96 in 2023 from RMB 1.58 in 2022[2] - Total reportable segment gross profit for 2023 was RMB 506,351 thousand, up from RMB 392,523 thousand in 2022, a 29.0% increase[23] - The company's pre-tax loss for 2023 was RMB 380,156 thousand, compared to RMB 601,353 thousand in 2022[33] - The company's net loss narrowed by approximately 36.4% in 2023, with plans to achieve near break-even by the end of 2024 through further expansion into high-margin overseas markets and cost control[44] - Gross profit increased by 29.2% from RMB 391.8 million in 2022 to RMB 506.0 million in 2023, driven by increased revenue from model animal sales and antibody development[106] - Gross margin decreased from 73.4% in 2022 to 70.6% in 2023, primarily due to the relocation to a new laboratory in Boston, USA, which reduced the gross margin of preclinical pharmacology and antibody development[106] - The company reported a net loss of RMB 383.0 million in 2023, compared to a net loss of RMB 602.2 million in 2022[117] R&D and Innovation - R&D expenses decreased by 32.2% to RMB 474.4 million in 2023 from RMB 699.2 million in 2022[3] - R&D expenses decreased by 32.2% to RMB 474.4 million in 2023 from RMB 699.2 million in 2022, as the company concluded its large-scale R&D investment phase[43] - R&D personnel totaled 366 as of December 31, 2023, with R&D expenses of RMB 474.4 million in 2023, down from RMB 699.2 million in 2022[89] - Core product R&D expenses were RMB 65.5 million in 2023, accounting for 13.8% of total R&D expenses[89] - R&D expenses decreased by 32.2% from RMB 699.2 million in 2022 to RMB 474.4 million in 2023, mainly due to reduced employee costs, outsourcing fees, and direct material costs[112] - The company's antibody development platform, RenMice, has generated a library of 400,000 to 500,000 antibody sequences for over 1,000 targets, enabling the identification of potential therapeutic antibody molecules[44] - The company's preclinical research services, including gene editing and model animal sales, have gained recognition from both domestic and international clients, contributing to rapid revenue growth and high margins[44] - The company's strategy involves advancing a small number of promising drug molecules to the preclinical stage and then partnering with biotech and pharmaceutical companies for further development and commercialization[45] - The company has completed the development of the "Thousand Mice Ten Thousand Antibodies" project and built a large antibody sequence library by the end of Q3 2023[46] - The "Thousand Mice Ten Thousand Antibodies" project has evaluated approximately 1,000 targets and developed over 800 targets, with a library of 400,000 to 500,000 fully human antibody sequences covering more than 1,000 innovative targets[48] - The company has knocked out over 680 target genes in RenMab and over 270 target genes in RenLite as part of the "Thousand Mice Ten Thousand Antibodies" project[48] - The company plans to expand the antibody library by developing bispecific antibodies and nanobodies using RenLite and RenNano technology platforms[48] - The company's business model involves commercializing antibodies through co-development, authorized transfers, and transfer development agreements, generating revenue from upfront payments, milestone payments, and sales royalties[48] - The company's revenue currently comes mainly from upfront payments, with milestone payments and sales royalties expected to grow significantly in the future[48] - The company's gene editing technology supports antibody discovery and model animal platforms, including the RenMice platform[79] - The company's gene editing services focus on overseas pharmaceutical clients to enhance profitability and value contribution[78] - The company's gene editing platforms include SUPCE, CRISPR/EGE, and ESC/HR, driving technological innovation[80] - The company provides customized gene editing services for rats/mice and cell lines, with final products including animal or cell line models with specific genotypes, genotyping reports, and project completion reports[81] - The company's proprietary SUPCE technology enables chromosome editing on a million-base scale, with high stability and repeatability, as demonstrated by the RenMice platform[82] - The RenMice platform has been licensed to several multinational pharmaceutical companies, including Merck Healthcare KGaA, Johnson & Johnson, Xencor, BeiGene, and Innovent Biologics, generating upfront payments, milestone payments, and sales royalties[83] - The RenMab platform, which uses RenMab mice to discover and generate fully human monoclonal antibodies, has obtained patents in China and the United States in 2023[84] - The RenLite platform generates high-affinity bispecific antibodies and bispecific ADCs, with the ability to produce bispecific ADCs targeting two tumor antigens, such as YH012 and YH013[85][86] - The RenNano platform produces fully human single-chain antibody fragments without the need for in vitro humanization, enabling high-throughput development of fully human heavy-chain antibodies[87] - The RenTCRm platform, based on RenMice, generates fully human antibodies targeting intracellular antigens, providing more candidate molecules for antibody-related drugs and CAR-T therapies[88] - GPCR platform developed based on RenMice, generating highly diverse fully human antibodies with high screening success rates[89] Clinical Trials and Drug Development - YH001 achieved an objective response rate (ORR) of 19.2% (95% CI: 6.6, 39.4) and a disease control rate (DCR) of 61.5% (95% CI: 40.6, 79.8) in a Phase I trial with 26 evaluable patients[50] - YH001 is being evaluated in a Phase I/II trial in the US for advanced or metastatic sarcoma, with 176 patients expected to be enrolled[51] - YH003 demonstrated a complete response (CR) in one patient with pancreatic cancer, who maintained CR status as of June 30, 2023[52] - YH003 Phase II MRCT enrolled 92 PDAC patients, with 47 in the first-line treatment group and 45 in the second-line and beyond treatment group[52] - YH003006 study in China enrolled 20 patients for the treatment of unresectable/metastatic mucosal melanoma, with results expected in the first half of 2024[53] - YH003005 study enrolled 15 patients for the treatment of advanced solid tumors in China and Australia[54] - YH002 Phase I trial showed a disease control rate (DCR) of 20% in 15 patients with advanced solid tumors[55] - YH002 was well-tolerated at doses up to 2.0mg/kg, with 46.7% of patients experiencing treatment-related adverse events (TEAEs)[55] - YH002 reported 3 serious adverse events (SAEs) at the 3.0mg/kg dose level, with no drug-related deaths[55] - YH002 demonstrated disease stabilization (SD) in 3 out of 15 patients based on RECIST v1.1 criteria[55] - YH002 has entered clinical trials in Mexico with promising initial clinical data showing anti-tumor activity[56] - YH004 Phase I clinical trial enrolled 17 patients with doses ranging from 0.01mg/kg to 3.0mg/kg, showing good safety and tolerability[57] - YH005 (RC118) received two orphan drug designations from the FDA for gastric and pancreatic cancer treatment[58] - YH008 secured a licensing deal with Microcore New Domain, including a RMB 40 million upfront payment and up to RMB 556 million in milestone payments[60] - YH012, a HER2/TROP2 bispecific ADC, entered an exclusive option and licensing agreement with Radiance in January 2024[61] - YH013, an EGFR/MET bispecific ADC, signed an exclusive option and licensing agreement with Doma Medical in 2023[62] - YH015, a CD40-targeting antibody, is currently in the CMC stage with potential applications in autoimmune diseases and organ transplantation[63] - YH016 and YH017, novel antibodies targeting myeloid cells and T/NK cells, have identified high-affinity candidate antibodies for further development[64] - YH001 is a recombinant humanized anti-CTLA-4 IgG1 monoclonal antibody[142] - YH002 is a recombinant humanized IgG1 antibody targeting the human OX40 receptor[142] - YH003 is a recombinant humanized agonistic anti-CD40 IgG2 monoclonal antibody[142] - YH004 is a humanized IgG1 anti-4-1BB agonist[142] - YH008 is an anti-PD-1/CD40 bispecific antibody for the treatment of solid tumors[142] - YH012 and YH013 are two bispecific ADCs developed using the RenLite platform, planned for the treatment of solid tumors[142] - YH015 is a fully human IgG1 anti-CD40 monoclonal antibody[142] - YH016 and YH017 are two novel molecules developed using the RenMice platform for the treatment of solid tumors and immune diseases, respectively[143] - 4-1BB is a receptor expressed on activated T cells and NK cells, providing co-stimulatory signals to promote T cell proliferation, survival, and cytotoxic effects[143] Financial Position and Expenses - Cash and bank balances decreased by 33.4% to RMB 417.7 million in 2023 from RMB 626.6 million in 2022[4] - Total equity decreased by 31.3% to RMB 790.4 million in 2023 from RMB 1,150.8 million in 2022[7] - The remaining performance obligation under existing contracts as of December 31, 2023, was RMB 182,160 thousand, expected to be recognized over the next 3 years[14] - Other income and losses net amount for 2023 was RMB 42,259 thousand, compared to RMB 86,710 thousand in 2022[25] - Net fair value change of biological assets for 2023 included realized fair value negative change of RMB 59,940 thousand and unrealized fair value positive change of RMB 64,819 thousand[26] - Financial costs for 2023 increased to RMB 99,844 thousand from RMB 56,139 thousand in 2022, mainly due to higher interest on long-term payables[27] - Employee costs for 2023 decreased to RMB 404,065 thousand from RMB 419,895 thousand in 2022, with a notable increase in equity-settled share-based payment expenses[28] - Depreciation of property, plant, and equipment for 2023 was RMB 182,299 thousand, up from RMB 171,034 thousand in 2022[31] - The company enjoyed a preferential tax rate of 15% in 2023 due to its high-tech enterprise qualification[34] - Basic loss per share for 2023 was calculated based on a net loss attributable to ordinary shareholders of RMB 382,951 thousand[35] - Trade receivables as of December 31, 2023, amounted to RMB 142,205 thousand, up from RMB 107,682 thousand in 2022[38] - The aging analysis of trade receivables showed that 88.5% were within 1 year, 10% were 1-2 years, and 1.5% were 2-3 years as of December 31, 2023[39] - Trade payables and notes payable increased to RMB 175,234 thousand in 2023 from RMB 146,190 thousand in 2022, with a significant rise in payables to third parties from RMB 104,968 thousand to RMB 115,113 thousand[40] - The company's issued and fully paid ordinary shares increased to 399,398 thousand shares by the end of 2023, following the issuance of 24,468 thousand new shares in 2022[41] - Sales costs increased by 48.4% from RMB 142.1 million in 2022 to RMB 210.9 million in 2023, in line with revenue growth[105] - Other income and losses decreased by 51.3% from RMB 86.7 million in 2022 to RMB 42.3 million in 2023, mainly due to a decrease in fair value changes of financial assets and foreign exchange gains[107] - Sales and marketing expenses increased by 25.0% from RMB 50.2 million in 2022 to RMB 62.8 million in 2023, largely due to salary increases in line with revenue growth[110] - General and administrative expenses increased by 8.7% from RMB 263.4 million in 2022 to RMB 286.3 million in 2023, primarily due to increased depreciation, amortization, and rental expenses from the new Boston facility[111] - Cash and cash equivalents decreased from RMB 626.6 million in 2022 to RMB 417.7 million in 2023, primarily due to net operating losses[114] - Financial costs increased by 77.9% from RMB 56.1 million in 2022 to RMB 99.8 million in 2023, driven by higher interest on long-term payables and bank loans[116] - The asset-liability ratio increased from 1.43 in 2022 to 2.10 in 2023, reflecting higher liabilities relative to equity[118] - Total capital expenditure for the year ended December 31, 2023, was approximately RMB 79.8 million, primarily for facility and office building investments and scientific equipment purchases[120] - The company mortgaged its factory and buildings in Baiao Situ Daxing for long-term bank loans, with a net book value of RMB 239,542,000 as of December 31, 2023[121] - Net proceeds from the global offering amounted to approximately HKD 537.0 million (equivalent to RMB 436.3 million), with 70% allocated to core product clinical R&D[125][126] - As of December 31, 2023, the company had utilized HKD 480.5 million of the net proceeds, leaving HKD 56.5 million unused, which is expected to be fully utilized by December 31, 2024[126][127] - The company allocated 35% of the net proceeds (HKD 188.0 million) to YH003 R&D and 35% (HKD 188.0 million) to YH001 clinical development[126] - 15% of the net proceeds (HKD 80.6 million) was used for facility construction and equipment procurement under the "Thousand Mice, Ten Thousand Antibodies" program[126] - The company has no significant contingent liabilities or major investments as of December 31, 2023[120][121] - The company has not conducted any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the year[122] - The company’s audit committee reviewed and confirmed compliance with accounting standards and regulations for the financial year ended December 31, 2023[128] - The board has decided not to recommend a final dividend for the year ended December 31, 2023 (2022: none)[130] - The company will suspend share transfer registration from May 23, 2024, to May 28, 2024, to determine shareholder eligibility for the annual general meeting on May 28, 2024[130] - The annual report for the year ended December 31, 2023, will be sent to shareholders and published on the Hong Kong Stock Exchange and the company

Financial Performance - Biocytogen Pharmaceuticals reported a significant increase in revenue, achieving a total of RMB 500 million for the first half of 2023, representing a 25% year-over-year growth[2]. - Revenue for the first half of 2023 reached RMB 326,836,000, a 42.6% increase compared to RMB 229,131,000 in the same period of 2022[13]. - Gross profit for the first half of 2023 was RMB 235,364,000, reflecting a 41.0% increase from RMB 166,970,000 year-on-year[13]. - Loss before taxation narrowed to RMB (189,389,000) in the first half of 2023, a 30.5% improvement from RMB (272,593,000) in the same period of 2022[13]. - Loss for the period attributable to equity shareholders decreased by 30.3%, from RMB (272,385,000) in 2022 to RMB (189,808,000) in 2023[13]. - The company maintained over 40% rapid growth in sales revenue in the first half of 2023, particularly in overseas markets[17]. - The company’s operational efficiency improvements led to a reduction in losses by approximately 30% year-on-year in the first half of 2023[18]. - The company expects to achieve profitability in 2025, with a continued narrowing of losses anticipated in 2024[127]. Market Expansion and Strategy - Biocytogen has set a future revenue guidance of RMB 1.2 billion for the full year 2023, indicating an expected growth of 30% from 2022[4]. - The company is focusing on market expansion, targeting an increase in its market share by 15% in the Asia-Pacific region by the end of 2023[6]. - The company’s board of directors has approved a new strategic initiative to enter the European market, with plans to establish a local office by Q4 2023[11]. - The company plans to enhance its digital marketing strategies, expecting a 20% increase in online engagement with potential customers[10]. - The company is actively developing new products, with 5 new drug candidates entering clinical trials in the first half of 2023[5]. Research and Development - The company is investing in advanced technologies, allocating RMB 100 million towards R&D for innovative drug development in 2023[8]. - The overall R&D strategy focuses on self-directing early discovery of drug molecules and advancing promising candidates to pre-clinical or early clinical stages[21]. - The company has established animal model production centers covering approximately 55,000 sq.m., allowing for a broad set of genetically engineered mice and disease models[110]. - The company has developed hundreds of syngeneic and xenogeneic tumor models to meet client scientific objectives[60]. - The company has developed a series of humanized mice based on the C57BL/6 genetic background to ensure effective drug validation for immune checkpoints and other targets[81]. Clinical Trials and Drug Development - The Phase I clinical trial of YH003 in combination with PD-1 in Australia is completed, with 26 patients enrolled, showing promising antitumor activity in certain cancers[25]. - Data from the Phase I clinical trial demonstrated that YH003 in combination with toripalimab was well tolerated, with three patients achieving partial response and one achieving complete response as of June 30, 2023[25]. - The ongoing Phase II MRCT study for YH003 in PDAC patients is expected to report results in 2024[27]. - YH004, a humanized anti-4-1BB IgG1 antibody, has completed the first patient dosing in Australia as part of its Phase I clinical trial, with 14 subjects enrolled as of June 30, 2023[28]. - The company has received IND approvals for YH003 from multiple regulatory bodies, including the U.S. FDA and NMPA, to conduct clinical trials in various countries[26]. Partnerships and Collaborations - The company is actively seeking strategic and synergistic partnerships with leading biopharmaceutical companies to enhance the success probability of its drug candidates and maximize their clinical and commercial value globally[21]. - The company has reached an exclusive clinical development and commercialization agreement for the YH008 bispecific antibody in Greater China, retaining global rights for YH008 outside of Greater China[23]. - The company is in cooperation with ISU ABXIS to develop a tri-specific antibody based on the YH003 sequence, entitled to receive upfront payments, milestone payments, and future sales royalties[23]. - The collaboration with RemeGen for YH005 has resulted in the development of RC118, which has received orphan drug designation from the U.S. FDA for gastric cancer treatment[48]. Financial Management and Investments - The company has submitted application materials for the proposed issuance of A-shares and received acceptance letters from the Shanghai Stock Exchange[111]. - The company has established a quality control system based on ISO9001, GMP, and GLP standards, with a quality management team of approximately 42 employees[115]. - The company has received a letter of acceptance from the Shanghai Stock Exchange for the proposed issue of A Shares[114]. - The company aims to achieve profitability by 2025, with a significant reduction in losses expected in 2024[124]. - The company has established 50 co-development/out-licensing/transfer development agreements as of June 30, 2023, including partnerships with Merck Healthcare KGaA and ADC Therapeutics, with a 45% increase in new deals signed in the first half of 2023 compared to the same period last year[51]. Employee and Operational Insights - The total number of employees as of June 30, 2023, was 1,313, a decrease from 1,348 as of December 31, 2022[162]. - The company has approximately 500 R&D personnel engaged in drug development and preclinical research services as of June 30, 2023[109]. - The management will continue to monitor foreign currency exposure and arrange hedging measures as necessary[157]. - The company has developed on-site training programs to enhance the skills of its personnel in cutting-edge scientific and technical topics[108].

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 326,836 thousand, representing a 42.6% increase compared to RMB 229,131 thousand for the same period in 2022[3]. - Gross profit for the same period was RMB 235,364 thousand, up 41.0% from RMB 166,970 thousand year-on-year[3]. - Loss before tax decreased to RMB 189,389 thousand, a 30.5% improvement from RMB 272,593 thousand in the prior year[3]. - The net loss for the period was RMB 189,809 thousand, reflecting a 30.4% reduction compared to RMB 272,593 thousand in the previous year[3]. - Basic and diluted loss per share improved to RMB 0.48, down 34.2% from RMB 0.73 in the same period last year[3]. - Total comprehensive loss for the period was RMB 190,098 thousand, a decrease of 30.2% from RMB 272,236 thousand in the prior year[3]. - Interest income for the six months ended June 30, 2023, was RMB 5,504,000, significantly higher than RMB 821,000 in 2022, representing a growth of 572.3%[24]. - The company reported a pre-tax loss of RMB 189,808,000 for the six months ended June 30, 2023, an improvement from a loss of RMB 272,385,000 in the same period of 2022[31]. - The company aims to achieve profitability by 2025, with expectations of continued narrowing of losses in 2024[94]. Revenue Breakdown - Gene editing services generated revenue of RMB 33,429,000, up 14.9% from RMB 29,252,000 in the previous year[15]. - Preclinical pharmacology and efficacy evaluation services saw revenue rise to RMB 89,541,000, a 36.8% increase from RMB 65,416,000[15]. - Sales of model animals increased significantly to RMB 115,219,000, compared to RMB 72,858,000, marking a 58.2% growth[15]. - Antibody development revenue grew to RMB 88,245,000, up 43.8% from RMB 61,345,000[15]. - Revenue from external customers in China for the six months ended June 30, 2023, was RMB 154,187,000, up from RMB 141,002,000 in 2022, reflecting a growth of 9.3%[22]. - Revenue from the United States increased significantly to RMB 116,577,000 for the six months ended June 30, 2023, compared to RMB 62,736,000 in 2022, marking an increase of 85.8%[22]. Assets and Liabilities - Non-current assets as of June 30, 2023, totaled RMB 1,871,267 thousand, slightly down from RMB 1,880,536 thousand at the end of 2022[7]. - Current assets decreased to RMB 846,521 thousand from RMB 919,296 thousand at the end of 2022[7]. - Total liabilities increased to RMB 1,103,319 thousand as of June 30, 2023, compared to RMB 1,042,970 thousand at the end of 2022[8]. - The company's equity attributable to shareholders decreased to RMB 960,358 thousand from RMB 1,146,265 thousand at the end of 2022[8]. - Trade receivables as of June 30, 2023, were RMB 122,646,000, compared to RMB 114,750,000 as of December 31, 2022, reflecting an increase of 6.5%[34]. - The total trade payables and notes payable as of June 30, 2023, were RMB 124,881 thousand, down 14.6% from RMB 146,190 thousand as of December 31, 2022[36]. Research and Development - The group continues to focus on research and development in innovative drug development, particularly in oncology and autoimmune diseases[19]. - The product pipeline includes 10 strategically designed antibody drug candidates, with five in clinical stages and five in preclinical stages as of June 30, 2023[39]. - The company has adjusted its R&D strategy to collaborate with more partners, such as the YH008 pipeline, to improve R&D efficiency and control costs[37]. - The company has established a model animal production center covering approximately 55,000 square meters, providing significant cost advantages[86]. - R&D expenses for the six months ended June 30, 2023, were RMB 248.0 million, compared to RMB 327.8 million for the same period in 2022, representing a decrease of approximately 24.3%[85]. - The company has discovered or developed 10 candidate drugs as of June 30, 2023, through its internal R&D capabilities[84]. Clinical Trials and Product Development - YH003, a humanized IgG2 monoclonal antibody targeting CD40, is in clinical trials for advanced solid tumors, with 26 patients enrolled in the Phase I trial in Australia[43]. - The company has initiated a Phase II multi-regional clinical trial for YH003 in combination with anti-PD-1 therapy for pancreatic ductal adenocarcinoma (PDAC), with 92 patients enrolled as of June 30, 2023[44]. - YH001 demonstrated an objective response rate of 19.2% (95% CI: 6.6, 39.4) and a disease control rate of 61.5% (95% CI: 40.6, 79.8) in a clinical trial with 29 patients[47]. - The company has received IND approvals from multiple regulatory agencies, including the FDA and NMPA, for various clinical trials[44]. - The ongoing studies for YH003 are expected to yield results in 2024, indicating a strong pipeline for future growth[44]. Strategic Initiatives - The company plans to seek strategic partnerships with leading biopharmaceutical companies to enhance the success rate of its drug candidates[39]. - The company is focusing on expanding its overseas market presence while leveraging its technical advantages in various business lines[37]. - The company has entered into an exclusive licensing agreement for YH008 with Microchip Biotech, receiving an upfront payment of RMB 40 million and potential milestone payments up to RMB 556 million[53]. - The company is actively exploring new model animals and cell detection models, focusing on tumor and autoimmune disease models for drug development[68]. - The company has signed a technology transfer agreement with Syncromune to develop and commercialize YH002, with Syncromune paying an upfront fee and potential milestone payments[52]. Corporate Governance and Compliance - The audit committee consists of four members, including one non-executive director and three independent non-executive directors, ensuring compliance with listing rules[119]. - The independent auditor, KPMG, reviewed the interim financial data according to the Hong Kong Institute of Certified Public Accountants' standards[120]. - The company is committed to adhering to the corporate governance code as outlined in the listing rules[124]. - The company emphasizes the importance of internal controls and risk management in its financial reporting processes[119].

Overseas Business Expansion - Overseas business grew rapidly in 2022, with over 2,800 models developed and more than 2,000 pre-clinical pharmacology and efficacy evaluation services provided to over 400 global clients[4][5] - The company established an innovation center in Germany in 2022 and is expanding its facility in Boston, USA, to accelerate globalization[8] - The company expanded its overseas sales team and established a German subsidiary in 2022, leading to significant sales growth in preclinical pharmacological efficacy evaluation and CRO services[57] - Overseas business revenue and its proportion of total revenue continue to increase, with a new subsidiary established in Heidelberg, Germany in 2022 and expansion of the Boston experimental facility[93] - The company will expand its overseas drug R&D service market to promote rapid growth in overseas sales revenue[155] RenMice Platform Development - The RenMice platform expanded with the addition of RenNano mice, enabling development in fully human monoclonal antibodies and nanobodies[6] - The company out-licensed its RenMice platform to well-known pharmaceutical companies such as Merck KGaA, Beigene, and Janssen under Johnson & Johnson, highlighting its innovation strength[7] - The company’s antibody development business utilizes the RenMice platform to form a library of 400,000 to 500,000 antibody sequences for over 1,000 targets, enabling the identification of potential therapeutic antibody molecules[12] - The RenMice platform consists of three chromosome-engineered mice (RenMab, RenLite, RenNano) and has enabled the development of a new TCRm technology platform for intracellular target antibody drug development[52] - RenMab platform enables the generation of fully human monoclonal antibodies with subnanomolar affinity and specificity, utilizing RenMab mice with full human heavy and kappa light chain variable region replacement[53] - RenLite platform produces high-affinity bi-specific antibodies and ADCs, with YH012 and YH013 currently at CMC stage, targeting two tumor-associated antigens to overcome non-tumor cytotoxicity[53] - RenNano platform produces fully human single-chain antibody fragments without in vitro humanization, saving time and cost, and enabling high-throughput development of heavy chain antibodies with nM-level affinity[55] - TCRm platform generates fully human antibodies targeting intracellular MAP epitopes, with higher affinity and specificity than TCR, enabling effective targeting of intracellular antigens[55] Project Integrum Progress - Project Integrum is progressing smoothly, with the company expected to complete most of the project by Q3 2023, generating 400,000-500,000 fully human antibody sequences for over 1,000 innovative targets[6] - The company aims to complete Project Integrum to access high-quality antibody molecules with abundant epitope recognition, leveraging its innovative drug R&D platforms[9] - By Q3 2023, Project Integrum is expected to complete most of its work, generating a library of 400,000 to 500,000 fully human antibody sequences covering more than 1,000 innovative targets[52] - Project Integrum (千鼠萬抗) has knocked out more than 680 target genes in target KO RenMab and over 260 target genes in target KO RenLite as of December 31, 2022[52] - The company's annual sales revenue from Project Integrum is currently driven by upfront fees, with milestone fees and royalties expected to grow significantly as more antibody molecules/sequences are transferred[51] Drug Pipeline and Development - The company achieved a major breakthrough in 2022 with diversified business models, including pre-clinical products and services, which sustained steady growth, and antibody development business, which offers high potential for revenue and long-term growth[7] - In 2022, the company adjusted its drug pipeline development priorities, establishing 11 selected antibody drug product pipelines, including fully human monoclonal antibodies, bispecific antibodies, and bispecific antibody ADC[7] - Four out of six clinical-stage drug candidates have reached out-licensing or transfer deals with partners like Tracon and Syncromune, with positive R&D progress[7] - YH005 ADC (RC118), out-licensed to RemeGen, received two orphan drug designations from the U.S. FDA and is progressing smoothly in clinical research[7] - YH008, a fully human dual antibody, has been approved by the FDA and NMPA for clinical trials, with an exclusive out-licensing agreement for Greater China with Chipscreen NewWay[7] - The company has strategically built a pipeline of 11 drug candidates, including 6 clinical-stage and 5 pre-clinical stage candidates as of December 31, 2022[13][15] - Four of the drug candidates have out-licensing arrangements with different collaborators, all discovered through the company's proprietary antibody discovery platform[16] - Core products include YH003, a humanized IgG2 agonistic monoclonal antibody targeting CD40, and YH001, a humanized anti-CTLA-4 IgG1 monoclonal antibody[14][17] - The company's R&D strategy focuses on self-directing early clinical development, then co-developing/transferring development to biotech and biopharmaceutical companies for Phase II/III clinical development and commercialization[16] - YH001 is being co-developed with Tracon for selected indications, with the company receiving double-digit tiered net sales royalties in North America and retaining rights outside North America[20][21] - YH002 intratumoral combination therapy has been licensed to Syncromune, with the company entitled to upfront payments, milestone payments, and tiered net sales royalties[20][21] - YH005 antibody has been licensed to RemeGen, with the company receiving upfront and milestone payments, and entitled to additional licensing fees for YH005-ADC development[21] - The company is collaborating with ISU ABXIS to develop a tri-specific antibody based on the YH003 sequence[21] - YH008 bispecific antibody has been exclusively licensed to Chipscreen NewWay for clinical development and commercialization in Greater China, while the company retains global rights outside Greater China[21] - The company currently has no plans to invest its own resources to lead Phase III clinical development and commercialization in the near future[16] Clinical Trial Progress - YH003 Phase I clinical trial in Australia enrolled 26 patients, with 20 in dose escalation and 6 in dose expansion stages[23][25] - YH003 Phase I trial determined RP2D at 0.3mg/kg, with 65.0% of subjects in Part I and 16.7% in Part II reporting Grade 3 or above adverse events[23][25] - YH003 Phase II MRCT for PDAC enrolled 47 subjects in first-line treatment 2C cohort and 45 subjects in second-line treatment 2B cohort as of December 31, 2022[26][28] - YH003 Phase II clinical trial for mucosal melanoma in China showed good clinical benefit in 9 evaluable subjects with no new safety signals as of December 31, 2022[26][29] - YH003 combined with PD-1 and YH001 Phase I trial enrolled 12 subjects for advanced solid tumors as of December 31, 2022[26][29] - YH003 Phase I trial in Australia reported 2 subjects with partial response (PR), including one with ocular melanoma achieving complete response (CR) after nearly 2 years[26][27] - YH003 Phase I trial in Australia reported 3 subjects with stable disease (SD), including one with NSCLC maintaining SD until database lock[26][27] - YH003 received IND approvals for Phase II MRCT from U.S. FDA, TGA, MedSafe, NMPA, and Taiwan FDA between June and November 2021[26][28] - YH003 Phase I trial in Australia reported 10 subjects (50.0%) in Part I and 1 subject (16.7%) in Part II experienced serious treatment-emergent adverse events (TEAEs)[23][25] - YH003 Phase I trial in Australia completed database lock on August 22, 2022, with no treatment-related serious TEAEs reported in both Part I and Part II[23][25] - YH004 Phase I clinical trial in Australia completed first patient dosing in December 2021, with 8 subjects enrolled as of December 31, 2022, receiving doses ranging from 0.01 mg/kg to 0.3 mg/kg[32] - YH001 Phase I clinical trial in Australia showed favorable safety and efficacy, with 5 out of 26 evaluable patients achieving partial response and 11 achieving stable disease as of December 31, 2022[38][39] - YH001/KN035SAR101 Phase I/II clinical trial in the US, sponsored by Tracon Pharmaceuticals, began patient recruitment in November 2022, targeting 176 patients with advanced or metastatic sarcoma[39] - YH001 received IND approval from the US FDA in October 2021 and NMPA approval in January 2022 for Phase I clinical trials in China[32] - YH001 combined with toripalimab showed good tolerability up to 4.0 mg/kg dose levels in Australia, with 26 out of 29 enrolled patients being evaluable[38][39] - YH001 Phase I clinical trial in China demonstrated good tolerability up to 6.0 mg/kg dose levels as a single agent for advanced solid tumors[38] - YH001/KN035SAR101 study aims to determine the recommended Phase II dose and objective response rate for various sarcoma types, with Phase I data expected by the end of 2023[39] - YH001 received U.S. FDA approval for Phase II clinical trial in June 2021, Taiwan FDA approval in October 2021, and NMPA approval in November 2021[40] - YH001 Phase I/II clinical trial in combination with envafolimab and doxorubicin for soft tissue sarcoma patients was approved by FDA in August 2022, with the first patient dosed in November 2022[40] - YH001/KN035SAR101 Phase I/II clinical trial, sponsored by Tracon Pharmaceuticals, is expected to enroll 176 patients in the U.S., with Phase I data expected by the end of 2023[41] - YH002 Phase I trial in Australia demonstrated a favorable safety profile, with IND approvals from NMPA and U.S. FDA for Phase I trials in China and the U.S.[42] - YH008, an anti-PD-1/CD40 bi-specific antibody, received U.S. FDA approval in December 2022 and NMPA approval in March 2023 for Phase I clinical trials in advanced solid malignant tumors[43][45] - YH005, an anti-Claudin 18.2 antibody, received Phase I clinical approval in Australia in August 2021 and in China in September 2021, with ongoing dose escalation studies showing good safety and tolerability[47] - YH005 received two orphan drug designations from the U.S. FDA for the treatment of gastric cancer, including gastroesophageal junction cancer, and pancreatic cancer[47] Financial Performance - Revenue increased by 50.6% from RMB354.6 million in 2021 to RMB533.9 million in 2022, driven by growth in pre-clinical pharmacology and efficacy evaluation, animal models selling, and antibody development[120][121] - Gross profit rose by 58.4% from RMB247.4 million in 2021 to RMB391.8 million in 2022, with gross profit margin increasing from 69.8% to 73.4%[123][125] - Cost of sales increased by 32.7% from RMB107.1 million in 2021 to RMB142.1 million in 2022, in line with revenue growth[121][122] - Other gains and losses, net, surged by 238.7% from RMB25.6 million in 2021 to RMB86.7 million in 2022, primarily due to gains from disposal of interest in an associate and changes in fair value of financial assets[124][126] - Net change in fair value of biological assets decreased by 60.2% from RMB9.8 million in 2021 to RMB3.9 million in 2022, primarily due to a lower increase in humanized mice stock (1,000 heads in 2022 vs. 7,600 heads in 2021)[127] - Selling and marketing expenses increased by 19.5% from RMB42.0 million in 2021 to RMB50.2 million in 2022, mainly due to salary increases[127] - General and administrative expenses increased by 40.0% from RMB188.1 million in 2021 to RMB263.4 million in 2022, driven by higher staff costs and listing expenses[127] - Research and development expenses increased by 25.2% from RMB558.5 million in 2021 to RMB699.2 million in 2022, primarily due to increased staff costs, direct material costs, and depreciation/amortization expenses[128][129] - Staff costs (excluding share-based payment) accounted for 31.9% of total R&D expenses in 2022, up from 30.9% in 2021[130] - Cash at bank and on hand increased from RMB466.4 million in 2021 to RMB626.6 million in 2022, mainly due to net proceeds from the Global Offering[131][132] - Net cash generated from financing activities was RMB587.2 million in 2022, compared to RMB219.4 million in 2021[134] - Financial costs increased by 42.4% from RMB39.4 million in 2021 to RMB56.1 million in 2022, primarily due to higher lease liability interest[135] - Income tax expense was RMB0.8 million in 2022, compared to zero in 2021[136] - The company reported a net loss of RMB602.2 million in 2022, compared to RMB545.6 million in 2021[136] - Finance costs increased by 42.4% to RMB56.1 million in 2022, primarily due to higher interest on lease liabilities[137] - Income tax was RMB0.8 million in 2022, compared to nil in 2021[138] - The company incurred losses of RMB602.2 million in 2022, up from RMB545.6 million in 2021[139] - Outstanding loans totaled RMB178.8 million as of December 31, 2022, with interest rates ranging from 3.65% to 6.0%[140][143] - Gearing ratio increased to 1.43 in 2022 from 0.84 in 2021[140][143] - Net current assets decreased to RMB313.3 million in 2022 from RMB427.7 million in 2021[141][144] - Total capital expenditure for 2022 was RMB410.6 million, primarily for facility and office building investments and scientific equipment purchases[146] - The company's equity in Doma Biopharmaceutical was diluted from 100% to 18.26% after a RMB940 million capital increase by investors and a RMB200 million subscription by the company[146] R&D and Innovation - The company has developed over 2,800 unique gene-edited mouse/cell line projects for antibody discovery and disease modeling[74][76] - The company launched hundreds of new animal models annually, contributing to satisfactory sales growth in 2022[77] - The company is expanding its animal models into neurological, cardiovascular, and metabolic diseases, in addition to its focus on tumor and autoimmune diseases[79][81] - The company has developed humanized mouse models for immune checkpoints and other targets, enabling pre-clinical evaluation of human antibody drugs[80][82] - The company's B-NDG mice, with severe immunodeficiency, are ideal for human cell and tissue transplantation studies[85] - The company humanized key cytokines and cytokine receptors in mice to evaluate the efficacy of human cytokine or cytokine receptor antibody drugs[84][86] - The company leverages its animal facility in Nantong, Jiangsu Province, to scale production and serve more customers[77] - The company typically signs 1-5 year framework agreements with clients and requires full payment within one month of invoicing[85] - The company's pre-clinical CRO business continues to grow rapidly with a high gross profit margin, maintaining long-term cooperation with nine of the top ten overseas pharmaceutical companies[93] - The company's antibody discovery business has grown at a high rate since 2020, maintaining a very high gross profit margin, with customer base expanding from domestic biotech companies to global pharmaceutical companies[94] - The company has developed a series of second-generation products based on B-NDG mice, including B-NDG B2m KO plus, B-NDG hIL15, and B-NDG hTHPO mice, to address specific research needs[89][91] - As of December 31, 2022, the company's R&D team has discovered and/or developed 11 drug candidates in its current pipeline[96] - The company has approximately 550 R&D personnel across three service centers, with 100 responsible for gene editing and animal models, 150 for pre-clinical pharmacology, 230 for antibody development, and 50 for clinical development[96] - R&D expenses for the year ended December 31, 2022, were RMB 699.2 million, with RMB 105.0 million (15.0%) allocated to core product development[97] - The company has established a model animal production center with three animal bases covering approximately 55,000 square meters, providing significant cost advantages[98] - The company collaborates with CROs and CDMOs for the development and clinical trials of its pipeline products, with CROs providing pre-clinical toxicity and safety evaluation services[99] - R&D expenses for the year ended December 31, 2022 were RMB699.2 million, with RMB105.0 million allocated to Core Products, accounting for 15.0% of total R&D expenses[100] - The company's quality management department consisted of approximately 45 employees as of December 31, 2022, with team members experienced in successful drug filings to the U.S. FDA and NMPA[103] - The company operates three animal model production facilities totaling approximately 55,000 sq.m., enabling cost-effective production of genetically engineered mice and disease models[101] - As of December 31, 2022, the company had approximately 1,000 suppliers, with over 900 based in China[107] - Expenses for CROs and CDMOs related to Core Products R&D were RMB71.4 million for the year ended December 31, 2022[110] - The company holds 263 registered trademarks, 105 authorized patents, and 4 software copyrights as of December 31, 2022, with 300 patent applications filed across 5 countries/regions[111] - The company has been granted 5 patents related to Core Products and has submitted 30 patent applications for the same[111] Future Plans and Strategies - The company plans to establish 400,000-500,000 fully human antibody sequence libraries covering more than 1,000 innovative targets to deepen cooperation with domestic and international pharmaceutical companies[153][154] - The company aims

Financial Performance - Total revenue for the year ended December 31, 2022, was RMB 533,881,000, representing a 50.6% increase from RMB 354,555,000 in 2021[2] - Gross profit for the same period was RMB 391,750,000, up 58.3% from RMB 247,440,000 in the previous year[2] - The net loss for the year was RMB 602,157,000, compared to a net loss of RMB 545,643,000 in 2021, reflecting an increase in loss of 10.2%[3] - Basic and diluted loss per share for the year was RMB 1.58, compared to RMB 1.51 in 2021, indicating a 4.6% increase in loss per share[3] - Total comprehensive loss for the year amounted to RMB 600,716,000, compared to RMB 545,062,000 in the previous year[3] - The company reported a net gain of RMB 86,710,000 from other income and losses for the year ended December 31, 2022, compared to RMB 25,569,000 in 2021[19] - The pre-tax loss for the year ended December 31, 2022, was RMB 601,353,000, an increase from RMB 545,643,000 in 2021[26] - The company reported a loss of approximately RMB 602.2 million for the year ended December 31, 2022, compared to a loss of approximately RMB 545.6 million for the year ended December 31, 2021[103] - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-over-year increase of 25%[131] - The company reported a net profit margin of 15% for 2022, up from 12% in 2021[132] Revenue Breakdown - Revenue from gene editing services was RMB 61,075,000, up 19.4% from RMB 51,146,000 in 2021[10] - Revenue from preclinical pharmacology and efficacy evaluation services reached RMB 176,069,000, a 67.0% increase from RMB 105,607,000 in the previous year[10] - Revenue from model animal sales was RMB 169,328,000, representing a 57.5% increase compared to RMB 107,555,000 in 2021[10] - Antibody development revenue increased to RMB 126,887,000, up 43.2% from RMB 88,606,000 in 2021[10] - Revenue from external customers in the United States was RMB 178,993,000, significantly up from RMB 102,118,000 in 2021[17] Research and Development - Research and development expenses for the year were RMB 699,167,000, up from RMB 558,485,000 in 2021[3] - R&D expenses for the years ended December 31, 2021, and December 31, 2022, were RMB 558.5 million and RMB 699.2 million, respectively, with core product R&D expenses accounting for RMB 105.0 million, approximately 15.0% of total R&D expenses[81] - The company aims to maintain high profit levels and rapid growth in preclinical research and development services, leveraging its leading gene editing platform to develop new disease mouse models for various diseases[112] - The company plans to invest RMB 200 million in R&D for new technologies and product development in the next fiscal year[131] Clinical Trials and Product Development - YH003, a humanized IgG2 monoclonal antibody targeting CD40, is undergoing Phase I clinical trials in Australia, with 26 patients enrolled and a recommended Phase II dose of 0.3 mg/kg established[42] - The company has initiated a Phase II MRCT for YH003 combined with Trastuzumab in PDAC patients, enrolling 47 patients in the first-line treatment group and 45 in the second-line treatment group as of December 31, 2022[43] - A Phase II trial in China for YH003 combined with PD-1 and chemotherapy in mucosal melanoma patients showed good clinical efficacy with no new safety signals reported[44] - The company has successfully completed Phase II clinical trials for its lead product YH003, with promising efficacy results[133] Strategic Partnerships and Collaborations - The company has partnered with various firms for the development and commercialization of its drugs, retaining rights outside of North America for certain products[40] - The company is actively seeking strategic partnerships with leading biopharmaceutical companies to enhance the success rate of its candidate drugs[38] - The company has established 34 collaboration agreements with 21 pharmaceutical and biotech companies, enhancing its product pipeline and revenue potential[54] - The company has established licensing and trial collaboration agreements with 17 multinational pharmaceutical companies, including Merck Healthcare KGaA and Xencor, as of December 31, 2022[55] Market Expansion and Future Plans - The company plans to issue A-shares and list on the Shanghai Stock Exchange's Sci-Tech Innovation Board, pending shareholder and regulatory approvals[111] - The company is expanding its market presence in Europe, targeting a 30% market share in the next two years[130] - The company is exploring acquisition opportunities in the biotech sector to bolster its product pipeline[129] - The company plans to launch three new products in 2023, including YH001 and YH002, targeting specific cancer therapies[133] Financial Position and Investments - As of December 31, 2022, the company's cash and cash equivalents totaled approximately RMB 626.6 million, an increase from RMB 466.4 million as of December 31, 2021, primarily due to net proceeds from a global offering[100] - The company's financing activities generated net cash of RMB 587.2 million for the year ended December 31, 2022, compared to RMB 219.4 million for the previous year, indicating a significant increase in financing[101] - The company has no significant investments or major acquisitions as of December 31, 2022, but it diluted its ownership in a subsidiary, Doma Pharmaceutical Technology (Suzhou) Co., Ltd., from 100% to 18.26% after raising RMB 940 million from investors[109] Employee and Operational Insights - Employee costs for the year ended December 31, 2022, totaled RMB 419,895,000, up from RMB 349,960,000 in 2021, reflecting a growth of approximately 19.9%[22] - The company employed a total of 1,348 employees as of December 31, 2022, with a focus on competitive compensation and continuous education programs to enhance employee retention[110] - The company faced delays in clinical trials and CRO business order deliveries due to COVID-19 impacts, but no significant adverse effects on overall business performance were reported[90]

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 229,131,000, representing a 74.8% increase compared to RMB 131,055,000 for the same period in 2021[22]. - Gross profit for the same period was RMB 166,970,000, up 87.5% from RMB 89,074,000 year-over-year[22]. - Gross profit margin improved to 72.9%, an increase of 4.9 percentage points from 68.0% in the previous year[22]. - Loss from operations for the six months was RMB 244,101,000, a 6.6% increase compared to RMB 229,080,000 in the prior year[22]. - Loss before taxation was RMB 272,593,000, reflecting a 9.4% increase from RMB 249,276,000 in the same period last year[22]. - Total comprehensive income for the period was a loss of RMB 272,236,000, compared to a loss of RMB 248,925,000 in the previous year[22]. - Basic and diluted loss per share for the period was RMB (0.73), compared to RMB (0.69) in the same period of 2021, representing a 5.8% increase in loss per share[22]. Research and Development - The company is focusing on expanding its market presence and enhancing its product pipeline through ongoing research and development efforts[6]. - The company continues to invest in new technologies to enhance its competitive edge in the pharmaceutical industry[6]. - The company has strategically designed a selective antibody drug pipeline consisting of 12 drug candidates, including five clinical stage candidates and seven pre-clinical stage candidates[26]. - The drug development business is complemented by pre-clinical research services, including gene editing and pharmacology evaluations[25]. - The company aims to enhance its technical capabilities through internal R&D, collaborations, and acquisitions[76]. - The R&D expenses for the six months ended June 30, 2022, were RMB 327.8 million, with RMB 42.4 million allocated to Core Products, accounting for approximately 12.9% of total R&D expenses[79]. - The R&D expenses for the six months ended June 30, 2021, were RMB 210.9 million, indicating a year-over-year increase in R&D spending[79]. Product Pipeline and Clinical Trials - There are currently seven ongoing clinical trials and four planned clinical trials, indicating active development in the pipeline[27]. - The drug candidates target novel indications and demonstrate differentiated efficacy or safety profiles validated in clinical studies[27]. - YH003 is a humanized IgG2 agonistic monoclonal antibody targeting CD40, with clinical trials initiated in 2017[31]. - Phase I clinical trial data for YH003 showed good tolerability at doses up to 3.0 mg/kg, with 22 Grade 2 and 2 Grade 3 treatment-related adverse events reported among 26 subjects[33]. - YH001 is a humanized anti-CTLA-4 IgG1 monoclonal antibody, with research and development also initiated in 2017[36]. - Phase I clinical trial data for YH001 indicated good tolerability at doses up to 4.0 mg/kg, with 5 patients achieving partial response (PR) and 9 achieving stable disease (SD) among 25 evaluable patients[38]. - The company plans to explore further indications for YH001 and YH003 through co-development and additional clinical trials[38]. Financial Position and Cash Flow - As of June 30, 2022, the company's cash and cash equivalents totaled RMB 347.0 million, down from RMB 466.4 million as of December 31, 2021, mainly due to net losses from operations[115]. - The company reported a net cash used in operating activities of RMB 111.2 million for the six months ended June 30, 2022, compared to RMB 156.5 million for the same period in 2021[116]. - The company experienced a net decrease in cash and cash equivalents of RMB 142.2 million for the six months ended June 30, 2022[116]. - Total capital expenditure for the six months ended June 30, 2022, was approximately RMB 131.6 million, primarily for facility investment and scientific equipment purchases[122]. Market Strategy and Future Outlook - Future outlook includes strategic initiatives aimed at improving operational efficiency and exploring potential mergers and acquisitions to drive growth[6]. - The company plans to partner with influential principal investigators in the domestic market to enhance brand awareness and develop commercialization strategies for core products[72]. - The company aims to leverage local partners for clinical development and commercialization in the competitive China oncology drugs market[72]. - The company is focused on transforming from an R&D-focused biotechnology company to a fully integrated biopharmaceutical company[89]. - The company plans to explore strategic partnerships with leading biopharmaceutical companies to enhance the success probability of its drug candidates[27]. Shareholder Structure and Employee Incentives - The total number of shares held by directors of Baiao Changsheng is 11,090,227, representing an effective interest of 59.47%[147]. - The company has established criteria for excluding individuals from participating in the Employee Incentive Schemes, including those without employment contracts or those convicted of crimes[150]. - The company’s employee incentive plans are designed to align the interests of core employees and senior management with those of shareholders[150]. - The company provides competitive salaries and stock incentive plans to retain key employees and enhance employee relations[129]. - As of August 13, 2022, the total number of shares granted to directors, supervisors, and senior management members was 38,731,320 shares, representing 10.33% of the company's total issued share capital[158]. Corporate Governance - The company is committed to high standards of corporate governance to safeguard shareholder interests[185]. - The roles of the chairman and chief executive officer are currently held by the same individual, Dr. Shen, which the Board believes ensures consistent leadership[185]. - The independent auditor, KPMG, conducted a review of the interim financial information in accordance with the Hong Kong Standard on Review Engagements[188]. - The company has adopted a code of conduct for securities transactions by Directors and Supervisors, compliant with the Model Code in Appendix 10 to the Listing Rules[184].